Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  • Equipment

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  • Equipment
  1. Outputs

Somatostatin analogs for gastric carcinoids : for many, but not all

Academic Article
Publication Date:
2015
Short description:
Somatostatin analogs for gastric carcinoids : for many, but not all / Massironi, S., Zilli, A., Conte, D.. - In: WORLD JOURNAL OF GASTROENTEROLOGY. - ISSN 1007-9327. - 21:22(2015), pp. 6785-6793. [10.3748/wjg.v21.i22.6785]
abstract:
Gastric carcinoids (GCs) are classified as: type I, related to hypergastrinemia due to chronic atrophic gastritis (CAG), type II, associated with Zollinger-Ellison syndrome in multiple endocrine neoplasia type 1, and type III, which is normogastrinemic. The management of type-I gastric carcinoids (GC1s) is still debated, because of their relatively benign course. According to the European Neuroendocrine Tumor Society guidelines endoscopic resection is indicated whenever possible; however, it is not often feasible because of the presence of a multifocal disease, large lesions, submucosal invasion or, rarely, lymph node involvement. Therefore, somatostatin analogs (SSAs) have been proposed as treatment for GC1s in view of their antisecretive, antiproliferative and antiangiogenic effects. However, in view of the high cost of this therapy, its possible side effects and the relatively benign course of the disease, SSAs should be reserved to specific subsets of "high risk patients", i.e. , those patients with multifocal or recurrent GCs. Indeed, it is reasonable that, after the development of a gastric neuroendocrine neoplasm in patients with a chronic predisposing condition (such as CAG), other enterochromaffin-like cells can undergo neoplastic proliferation, being chronically stimulated by hypergastrinemia. Therefore, definite indications to SSAs treatment should be established in order to avoid the undertreatment or overtreatment of GCs.
Iris type:
1.1 Articolo in rivista
Keywords:
Atrophic gastritis; Carcinoid tumors; Enterochromaffin-like cells; Lanreotide; Neuroendocrine tumors; Octreotide; Animals; Antineoplastic Agents; Carcinoid Tumor; Gastritis; Atrophic; Humans; Patient Selection; Risk Factors; Somatostatin; Stomach Neoplasms; Treatment Outcome; Gastroenterology
List of contributors:
Massironi, S.; Zilli, A.; Conte, D.
Authors of the University:
MASSIRONI SARA
Handle:
https://iris.unisr.it/handle/20.500.11768/172086
Published in:
WORLD JOURNAL OF GASTROENTEROLOGY
Journal
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.11.0.1